Riskpilot← Back to searchSign inGet full accessBERGEMOEN APOTEK AS
ASActiveOrg 926603167Bergemoveien 45, 4886 GrimstadRetail sale of pharmaceutical products · NACE 4773Est. 20217 employees
Revenue 2024
NOK 28,8M
+11% vs 2023
EBITDA margin
13.6%
+12% vs 2023
Equity ratio
18.4%
Financial strength
Net profit 2024
NOK 3M
+14% vs 2023
| Revenue | NOK 28,8M | +11% |
| EBITDA | NOK 3,9M | +12% |
| Net profit | NOK 3M | +14% |
| Total assets | NOK 5,9M | -26% |
| Equity | NOK 1,1M | +8% |
| Employees | 7 | — |
Legal name
BERGEMOEN APOTEK AS
Org number
926603167
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
16. februar 2021
Share capital
NOK 700 000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene. Daglig leder alene.
Company purpose
Eie og drive apotek, herunder konsulenttjenester innenfor apotekerbransjen og lege- og helserelaterte produkter, samt øvrig virksomhet i tilknytning til dette.
Address
Bergemoveien 45, 4886 Grimstad
Phone
+4741561415
Email
salg@bergemoen.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 9 680 | 19 357 | 25 900 | 28 818 |
| Staff expenses | −1 478 | −2 550 | −2 914 | −3 222 |
| EBITDA | 806 | 2 269 | 3 502 | 3 931 |
| Depreciation & amort. | −124 | −146 | −146 | −102 |
| EBIT | 682 | 2 123 | 3 356 | 3 829 |
| Net financials | −35 | −28 | −4 | −7 |
| Profit before tax | 647 | 2 095 | 3 352 | 3 823 |
| Tax | 149 | 469 | 747 | 846 |
| Net profit | 499 | 1 626 | 2 605 | 2 977 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 4 666 | 5 606 | 8 083 | 5 949 |
| Equity | 1 189 | 1 414 | 1 019 | 1 096 |
| Long-term debt | 1 373 | 0 | 0 | 0 |
| Short-term debt | 2 104 | 4 192 | 7 063 | 4 853 |
| Total debt | 3 478 | 4 192 | 7 063 | 4 853 |
EBITDA margin
13.6%
This company
15.8%
Market median
-14% vs market
20212024
Equity ratio
18.4%
This company
38.2%
Market median
-52% vs market
20212024
Return on equity
271.6%
This company
18.4%
Market median
+1376% vs market
20212024
Net profit margin
10.3%
This company
8.1%
Market median
+27% vs market
20212024
Asset turnover
4.84×
This company
1.12×
Market median
+332% vs market
20212024
Debt / equity
4.43×
This company
0.62×
Market median
-615% vs market
20212024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PM Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Board of Directors | 2023 | |
| Board of Directors | 2023 | |
| Former (1) | ||
| Board of Directors | 2022 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 80% | 80% | 2022 | |
| Company | 20% | 20% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Apoinvest Holding As
BERGEMOEN APOTEK AS Board members of BERGEMOEN APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Prince Muhammad Kashif | Chief Executive Officer | 0 companies |
| Pål Jørgen Nilsen | Board of Directors | 0 companies |
| Zeshan Munawar | Chairman | 0 companies |
| Atle Martin Haug | Board of Directors | 0 companies |
| Anam Ul Haq Anam Ul Haq | Board of Directors | 0 companies |
| Gulzeb Aziz | Board of Directors | 0 companies |